LPV/r 100/25mg Heat-Stable Tablets are a potent, film-coated medication for the treatment of HIV-1 infection. Precisely formulated for adults and children above two years, fostering extensive and efficient virus management.
Quality, stability, and versatility rolled into one for a more comprehensive HIV-1 treatment plan.
Effectively managing HIV is an ongoing quest in the health sector. An innovative solution in this arena is the LPV/r 100+25mg heat-stable tablets, which offer a unique combination of two potent antiretroviral agents, Lopinavir 100mg and Ritonavir 25mg, in a fixed-dose formulation. This robust blend provides powerful defense against HIV-1, streamlining the medication process to maximize patient compliance.
The heat-stable feature ensures that the medication maintains its potency even in fluctuating temperatures, making it ideal for use in varying environments. Moreover, each tablet coated with a protective film is packaged in bottles of 60 to guarantee safety and optimum therapeutic effectiveness.
The LPV/r 100+25mg heat-stable tablets belong to the Protease Inhibitors pharmacologic class. They are used in treating HIV-1 in adults and in children aged two years and above. For maximum therapeutic return, the oral administration of these tablets should be in conjunction with at least two other antiretroviral drugs.
Store the tablets at or lower than 30℃ in their original packaging, putting them out of sight and reach for children to ensure safety. For detailed information about the dosage, contraindications, and side effects, refer to the WHO treatment guidelines and applicable national regulations.
Lopinavir and Ritonavir, crucial components of these tablets, are protease inhibitors. They stymie the protease enzyme, which is necessary for the HIV virus to replicate in the human body. This halts the virus's proliferation, helping manage the HIV-/AIDS-causing viruses effectively.
Before starting any treatment involving LPV/r 100+25mg heat-stable tablets, seek advice from a healthcare professional. These tablets may not be suitable for patients with specific chronic liver conditions or those allergic to Lopinavir/Ritonavir. Potential side effects include nausea, vomiting, diarrhea, and changes in cholesterol and triglyceride levels.